Institutional investors purchased a net $3.9 million shares of MEIP during the quarter ended December 2012 and now own 38.10% of the total shares outstanding. This is a greater percentage than is typical for companies in the Pharmaceuticals: Other industry and highlights that the smart money sees this stock as an important holding.
| Mutual fund holders | 8.28% |
| Other institutional | 29.82% |
| Individual stakeholders | 12.09% |